Instruction 1(b).

## FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287

OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

		tion 16(a) of the			
(	JI 30(I	n) of the Investi	nent Compa	arry Act or 1	1940

1. Name and Address of Reporting Person* <u>DeLange Peter M.</u>				2. I <u>E</u> 1	2. Issuer Name <b>and</b> Ticker or Trading Symbol EnteroMedics Inc [ ETRM ]										ck all applic Directo	r		10% Ov	vner		
(Last) 2800 PA	(F TTON ROA	*	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 02/08/2017										below)	Officer (give title below)  SVP, Ops &		Other (s below) is Dev	pecify	
(Street) ST. PAUL MN 55113					4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)									Line)	6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person Form filed by More than One Reporting					
(City)	(S	tate)	(Zip)									Person									
		Tal	ole I - Nor	n-Deri	vativ	e Se	ecuritie	s Ac	quir	ed, D	isp	osed o	f, or B	ene	ficially	/ Owned					
Date			Date	nsaction h/Day/Year)		2A. Deemed Execution Date if any (Month/Day/Yea		Code (Instr.						Securitie Benefici Owned F	5. Amount of Securities Beneficially Owned Following		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership			
									Code		,	Amount	t (A) or (D)		Price	Reported Transact (Instr. 3	tion(s)			(Instr. 4)	
Common Stock																39	)1 <sup>(1)</sup>		D		
Common	mmon Stock														2	(1)		I	By Son		
			Table II -									sed of, onvertib				Owned					
Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day	Date,	Code (In		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisa Expiration Date (Month/Day/Yea				7. Title and Amor of Securities Underlying Derivative Secur (Instr. 3 and 4)		ecurity	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	e s ally	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exerc	isable		Expiration Date	Title	1	Amount or Number of Shares						
Option (Right to Buy)	\$96.6 <sup>(1)</sup>								01/18/	'2017 <sup>(2)</sup>	0	1/18/2026	Commo		2,380		2,380 <sup>0</sup>	(1)	D		
Option (Right to	\$7.12	02/08/2017			A		93,250		02/08/		$\left  \right _{0}$	2/08/2027	Commo	n c	93,250	\$0.00	93,25	io	D		

## Explanation of Responses:

- 1. On December 27, 2016, EnteroMedics Inc. effected a 1-for-70 reverse stock split of its issued and outstanding shares of common stock, par value \$0.01 per share, resulting in a proportional decrease in the total shares of common stock beneficially owned by the reporting person, all previously reported exercise prices, option grants and similar instruments convertible into common stock were proportionally adjusted to reflect the reverse split.
- 2. Vests 25% one-year from the date of grant on the date noted and thereafter in cumulative installments of 1/36th per month.
- 3. Vests immediately as to 25% on the date noted and thereafter in cumulative installments of 1/36th per month.

## Remarks:

EX 24: DeLange Power of Attorney Attached THIS FILING REFLECTS THE POST SPLIT NUMBERS OF ALL SHARES, OPTIONS AND SIMILAR INSTRUMENTS HELD BY THE REPORTING PERSON AS PREVIOUSLY REPORTED.

/s/ Scott P. Youngstrom,
Attorney in Fact for Peter M. 02/10/2017
DeLange

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Know all by these presents, that I hereby constitute and appoint each of Dan W. Gladney and Scott P. Youngstrom my true and lawful attorney-in-fact and agent, each acting alone, with full power of substitution for me and in my name, place and stead, to:

- execute for me and on my behalf, in my capacity as an officer and/or director of EnteroMedics Inc, Forms 3, 4 or 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended, and the rules promulgated thereunder;
- 2. do and perform any and all acts for me and on my behalf which may be necessary or desirable to complete and execute any such Form 3, 4 or 5, complete and execute any amendment or amendments thereto and timely file such Form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and
- 3. take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to me, in my best interest or legally required by me, it being understood that the documents executed by such attorney-in-fact on my behalf pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

I hereby grant to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as I might or could do if personally present, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted. I acknowledge that the attorneys-in-fact, in serving in such capacity at my request, are not assuming, nor is EnteroMedics Inc. assuming, any of my responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended.

This Power of Attorney shall remain in full force and effect until I am no longer required to file Forms 3, 4 and 5 with respect to my holdings of and transactions in securities of EnteroMedics Inc., unless earlier revoked by me in a signed writing delivered to the attorneys-in-fact named above.

IN WITNESS WHEREOF, I have signed this Power of Attorney on 4 October, 2016.

/s/ Peter M. DeLange Peter M. DeLange